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not respond well to conventional treatments. Thus, iso-
6-spectaline (SPEC) may possess a modulatory role in 
the treatment of neurodegenerative diseases, since their 
piperidine alkaloid compound can interrupt cellular oxidative 
processes in the CNS. The effects of SPEC on the CNS have 
not yet been determined, therefore, would be important to 
conduct these studies to clarify its brain action mechanism.
Piperidine alkaloids are abundant in nature and many 
of them are known to exhibit some biological activity. 
In our search for potential anxiolytic, antidepressant 
or anticonvulsant agents employing a mechanism-
based yeast bioassay for CNS-modifying agents,[1]   
we have isolated iso-6-spectaline (SPEC; 14-[(2R,3R,6R) 
INTRODUCTION
Numerous herbal medicines are recognized as active in 
the central nervous system (CNS), and they have at least 
a hypothetical potential to affect chronic conditions such 
as anxiety, depression, headaches or epilepsy, that do 
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ABSTRACT
The central nervous system (CNS) depressant and anticonvulsant activities of iso-6-spectaline (SPEC) 
were investigated in animal models. The SPEC from Senna spectabilis var. excelsa (Schrad) (0.1, 0.5 and 
1.0 mg/  kg) injected by oral route (p.o.) in mice caused a significant decrease in the motor activity up to 30 days 
after the administration and in the dose of 1.0 mg/kg significantly reduced the remaining time on the Rota-rod 
apparatus. Additionally, SPEC (0.1, 0.5 and 1.0 mg/kg, p.o.) was also capable of promoting increase of latency 
for development of convulsions induced by pentylenetetrazole. This SPEC was also capable of promoting an 
increase of latency for development of convulsions induced by picrotoxin at highest dose. In the same way, 
the anticonvulsant effect of SPEC was affected by pretreatment with flumazenil, a selective antagonist of the 
benzodiazepine site of the GABAA receptor. These results suggest possible CNS depressant and anticonvulsant 
activities in mice that needs further investigation.
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-3-hydroxy -2-methylpiperidine]-tetradecan-13-one), 
piperidine alkaloids, is a heterocyclic organic not aromatic 
compound [Figure 1] found in many plant species. It was 
isolated for the first time from Cassia sp., species previously 
known as Cassia excelsa, hence the term cassine.[2] Piperidine 
alkaloid derivatives with CNS effects include SPEC which 
exerts neuroprotective effects against depression model.[2]
In Brazilian northeast folk medicine, Senna spectabilis is 
used as anti-inflammatory, analgesic, laxative, purgative, 
antimicrobial and antiulcerogenic.[3-5] Studies have shown 
that the extract of Senna sp. inhibits lipid peroxidation 
of bovine brain phospholipids, indicating its antioxidant 
activity.[6] Then, the excessive production of free radicals in 
the organism, and the imbalance between the concentrations 
of these and the antioxidant defenses may be related to the 
pathogenesis of neurodegenerative diseases.[7,8]
The genus Cassia possesses about 600 species distributed 
worldwide, being well known due to its diverse biological 
and pharmacological properties.[4] Senna spectabilis (DC) Irwin 
and Barneby var. spectabilis (Cassia spectabilis DC) is widely 
grown as an ornamental plant in tropical and subtropical 
areas, and has been commonly used in traditional medicine 
for many years. It has also been used in traditional Brazilian 
medicine for the treatment of flu and cold, as a laxative and 
purgative.[9,10]
Preliminary behavioral screening realized with the SPEC 
demonstrates that it reduces lipid peroxidation in pilocarpine-
induced seizures, increasing survival rate and reducing 
number of seizures in rats. Additionally, there is no work 
demonstrating SPEC effects in neurodegenerative diseases in 
animal models of anxiety, depression or epilepsy. Therefore, 
we decided to assess the SPEC effects on the CNS of mice.
MATERIALS AND METHODS
Plant material and chemistry study
The plant was collected in September 2003, at Boa 
Viagem, State of Ceará, Brazil, and was identified by 
Prof. A.G. Fernandes, in the Department of Biology of 
the Federal University of Ceará. The voucher specimen 
is deposited at the Prisco Bezerra Herbarium under the 
voucher number 33013.
The botanical material, leaves (1.5 kg), stem (5.1 kg) 
and roots (3.8 kg), were triturated and exhaustingly 
extracted with ethanol and concentrated in rotative 
evaporator, producing 39 g, 27.5 g and 42 g respectively. 
The leaf extract (39 g) was then submitted to technical 
of selective extraction of alkaloids a fraction rich in 
alkaloids (FA) and a non alkaloids (FNA) were obtained. 
The alkaloid fraction was submitted to chromatography 
on SEPHADEX, with methanol as movable phase. The 
dichloromethane fraction (7.6 g) was submitted to the 
same chromatography process.
The analysis of the fractions was made in chromatography 
in thin layer (CCD), which revealed the purity of the 
rich fraction in SPEC (30 mg) which when subjected to 
the test with the reagent Dragendoff revealed an orange 
stain, and was thus positive for alkaloids.[11] Its spectra of 
NMR RMN1H, RMN13C, DEPT 135, COSY, HMBC e 
HSQC1 were obtained and compared with the data from 
the literature for identification. The iso-6-spectaline is an 
amorphous white solid with M.P. 130.8-132.3ºC; the value 
of TLC in MeOH/EtOAc (1:1), Rf = 0.58; NMR spectra 
description of 1H is 1H NMR (MeOD, 500 MHz) dH 3.83 
(1H, H-3); 3.30 (1H, H-6); 3.23 (1H, H-2); 2.47 (2H, H-12’); 
2.15 (3H, H-14’); 1.44 (3H, H-7); 1.29-1.33 (12H, H-4’ - 
H-9’); NMR spectra description of 13C is 13C NMR (MeOD, 
125 MHz) dC – 212.4 (C, C-13’); 66.1 (CH, C-3); 58.8 (CH, 
C-2); 57.7 (CH, C-6); 44.4 (CH2, C-12’); 34.9 (CH2, C-1’); 
31.2 (CH2, C-4); 29.9 (CH3, C-14’); 30.9 (CH2, C-3’); 30.5 
(CH2, C-10’); 30.5-30.9 (CH2, C-4’-C-9’); 26.4 (CH2, C-2’); 
23.8 (CH2, C-5); 23.8 (CH2, C-11’); 16.1 (CH3, C-7). In the 
present work, the iso-6-spectaline was suspended in 0.5% 
Tween 80 distilled in water, and sonicated before use. 
Agents were administrated orally (p.o.) and intraperitoneally 
(i.p.) at a dose volume of 0.1 ml/10 g.
Animals
Male Swiss mice (25-30 g), two months of age were used. 
The animals were randomly housed in appropriate cages 
at 23 ± 2◦C on a 12-h light/dark cycle (lights on 08:00 
a.m. – 18:00 p.m.) with free access to food (Purina®) and 
water. All experiments were carried out between 08:00 a.m. 
and 18:00 p.m. in a quiet room. Experimental protocols 
and procedures were approved by the Ethics Committee 
on Animal Experiments at the Federal University of Piaui 
(CEEA/UFPI # 44/09).
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Behavioral effects, locomotor activity and motor coordination test 
(rota-rod test)
Behavioral screening (n = 7, per group) was performed 
following parameters described by Almeida et al.,[12] 
and animals were observed at 30 days after oral (p.o.) 
administration of SPEC (0.1, 0.5, and 1.0 mg/kg, p.o.).
Mice were divided into four groups (seven animals each). 
Vehicle (saline/Tween 80 0.5%; control group) and SPEC 
(0.1, 0.5, and 1.0 mg/kg, p.o.) were injected. The spontaneous 
locomotor activity of the animals was assessed in a cage activity 
(50 cm × 50 cm × 50 cm) after 30 days of treatment.[13]
A Rota-rod treadmill device (AVS®, Brazil) was used for the 
evaluation of motor coordination.[14] Initially, the mice able to 
remain on the Rota-rod apparatus longer than 180  s (9 rpm) 
were selected 24 h before the test. Thirty minutes after 30 
days of administration of either SPEC (0.1, 0.5, and 1.0 mg/
kg, p.o.), vehicle (saline/Tween 80 0.5%; control group) or 
diazepam (DZP, 2.0 mg/kg, i.p.), each animal was tested 
on the Rota-rod apparatus and the time(s) remained on the 
bar for up to 180 s was recorded after 30 days of treatment.
Pentylenetetrazole-induced convulsions
Pentylenetetrazole (PTZ) (60 mg/kg, i.p.) was used to 
induce clonic convulsions.  [15] Mice were divided into five 
groups (n = 7 per group). First group received vehicle (two 
drops of Tween 80 0.5% in distilled water, the solvent for 
SPEC) while the second group was treated with diazepam 
(DZP, 2.0 mg/kg, i.p.). The remaining groups received an 
injection of SPEC (0.1, 0.5, and 1.0 mg/kg, p.o.). After 
30 days of drug administration, the mice were treated 
with PTZ (i.p.) at a dose of 60 mg/kg. The latency and 
percentage of inhibition clonic convulsions were registered. 
The incidence of deaths was noted until 24 h after the 
injection of PTZ.
The effect of selective GABAA-BZD receptor antagonist 
flumazenil[16] on the anticonvulsant activity of SPEC 
was investigated. In the experimental groups, mice were 
given flumazenil (FLU) (10 mg/kg, i.p.) 30 min before 
the administration of SPEC (1.0 mg/kg, p.o.) (30 days 
before the injection of PTZ). In the standard group, the 
animals received FLU 30 min before the administration 
of diazepam (DZP, 2.0 mg/kg, i.p.) (30 days before the 
injection of PTZ). The anticonvulsant activity of SPEC 
and DZP in mice pretreated with FLU was assessed.
Picrotoxin-induced convulsion
The method has been described previously.[17,18] Animals 
were divided into five groups (n = 7 per group). Control 
group received vehicle and standard group was treated with 
diazepam (DZP, 2.0 mg/kg, i.p.). The remaining groups 
were treated with 0.1, 0.5 and 1.0 mg/kg (p.o.) of SPEC. 
After 30 days of drug administration, the mice were treated 
with PIC at a dose of 8 mg/kg (i.p.). Immediately after the 
injection of the convulsant, mice were individually placed in 
plastic boxes and observed for the time to onset of clonic 
convulsion (latency), percent clonic convulsion and deaths. 
The incidence of deaths was noted until 24 h after the 
injection of PIC.
Statistical analysis
The data obtained were evaluated by one-way analysis 
of variance (ANOVA) followed by Student-Neuman-
Keuls t-test. The incidence (%) of clonic or tonic-clonic 
convulsions as well as the mortality were evaluated by 
Fisher`s Exact Test. Differences were considered to be 
statistically significant when P < 0.05.
RESULTS AND DISCUSSION
Analysis of the 1H NMR and 13C NMR spectra showed 
that SPEC presented analytical and spectroscopic data in 
full agreement with its assigned structure. The chemical 
purity of the compound was determined by analysis of 
the 1H NMR and 13C NMR.
SPEC at doses of 0.1, 0.5 and 1.0 mg/kg (p.o.) showed 
behavioral changes in animals 30 days after of treatment: 
Decrease of spontaneous activity, palpebral ptosis, ataxia, 
analgesia, and sedation. Behavioral changes were more evident 
on the second day of treatment. The doses of 0.1, 0.5 and 
1.0 mg/kg (p.o.) of SPEC caused significant decrease of 30%, 
30% and 59% of ambulation (number of crossings) 30 days 
after administration, respectively [Figure 2]. In this test only the 
highest dose (1.0 mg/kg, p.o.) reduced (40%) the remaining 
time of animals on the Rota-rod apparatus [Figure 3].
Figure 2: Effects of iso-6-spectaline (0.1, 0.5 and 1.0 mg/kg, p.o., 
SPEC) or diazepam (DZP, 2.0 mg/kg, i.p.) on locomotor activity of 
mice. The parameters evaluated were the total number of pulses of 
crossings in activity cage. Values are mean ± S.E.M. for seven mice per 
group. *P < 0.001 as compared to control (Vehicle), one-way ANOVA 
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Table 1 shows that (PTZ) consistently induced clonic 
convulsions in 100% of mice. SPEC (0.1, 0.5 and 
1.0 mg/kg, p.o.) delayed the onset of PTZ-induced tonic 
convulsion significantly and (1.0 mg/kg, p.o.) protected 
80% (P < 0.001) of mice against the convulsion. Diazepam 
completely protected the animals against the tonic 
convulsion elicited by PTZ.
As described in Table 1, the administration of FLU (10 mg/
kg, i.p.) antagonized the effect of SPEC (1.0 mg/kg, i.p.) 
and DZP (2 mg/kg, i.p.) in the prolongation of convulsion 
latency. When given i.p., only the highest dose of SPEC 
(1.0 mg/kg, i.p.) increased the latency for convulsions 
induced by PIC significantly when compared to the control 
(P < 0.001) [Table 2].
The antidepressant and anticonvulsants effects of SPEC 
isolated from S. spectabilis were emphasized in the present 
work since the management of neurodegenerative diseases 
faces a number of problems including limited number 
of effective antidepressant agents and toxicity of the 
available anticonvulsant agents. In folk medicine of the 
Brazilian Northeast, the Senna spectabilis is used as an anti-
inflammatory, analgesic, laxative, purgative, antimicrobial 
and antiulcerogenic.[3,4] In pharmacological behavioral 
screening, the animals treated with SPEC showed decrease 
of response to the touch, palpebral ptosis, ataxia, analgesia, 
sedation and reduction of motor activity. These data 
are indicative of the depressive activity of the CNS.,[2] 
indicating effects on the CNS similar to drugs that reduce 
the CNS activity.[5,10,19-23]
The reduction of the locomotor activity observed after 
treatement with SPEC an be due to either an inhibitory effect 
of the SPEC in the CNS or by muscular relaxant activity in 
the periphery. Our results suggest that SEPC could show 
a neuro-sedative activity or a profile for a hypnotic drug.
Our results suggest that the higher dose of SPEC produces 
loss of motor coordination in mice. Thus, the lack of motor 
coordination is characteristic of a drug that reduces the CNS 
activity such as anxiolytics, sedatives and hypnotics.[12,24,25]
Pentylenetetrazole, picrotoxin and strychnine are all 
convulsant agents.[26,27] Data from this study show that 
the onset of tonic-clonic convulsion produced by PTZ 
was significantly delayed by SPEC [Table 2] and mortality 
was significantly reduced (P < 0.05). According to De 
Sarro et al.,[28] PTZ may be exerting its convulsing effect 
by inhibiting the activity of gamma aminobutyric acid 
(GABA) at GABAA receptors. Gamma aminobutyric 
acid is the major inhibitory neurotransmitter implicated 
in epilepsy. The enhancement and inhibition of GABA 
neurotransmission will attenuate and enhance convulsion, 
respectively.[29] Since the SPEC delayed the occurrence 
of PTZ convulsion, it is probable that it may interfere in 
GABAergic mechanisms to exert its anticonvulsant effect.
In order to determine the role of BZD receptors in the 
SPEC-induced anticonvulsant effects, flumazenil (FLU), 
a specific antagonist of the benzodiazepine site in the 
GABA-benzodiazepine receptor complex, was used.[16] 
The results obtained from PTZ-induced convulsion model 
in mice pretreated with FLU suggest that SPEC could 









Vehicle - 156.3 ± 11.9 0 0
SPEC 0.1 0.1 279.0 ± 22.6a 0 0
SPEC 0.5 0.5 376.8 ± 38.0a, b 10 20e
SPEC 1.0 1.0 582.5 ± 33.5a, b, c 80d 30d
ISO + FLU 1.0 + 10 271.8 + 38.9 0 10e
DZP  2 862.9 ± 10.0a 100d 100d
DZP + FLU 2 + 10 171.2 + 15.2 0 15
Values are mean ± S.E.M. for seven mice per group. aP < 0.05 (ANOVA followed 
by Student-Neuman-Keuls t-test), significantly different from control; bP < 0.01 
(ANOVA followed by Student-Neuman-Keuls t-test), significantly different 
from SPEC 0.1; cP < 0.001 (ANOVA followed by Student-Neuman-Keuls t-test), 
significantly different from SPEC 0.5; dP < 0.001 (Fisher`s test), significantly 









Vehicle - 516.2 ± 14.5 0 0
DZP 2 1336.0 ± 10.0a 100a 100a
SPEC 0.1 0.1 518.5 ± 21.01 0 0
SPEC 0.5 0.5 517.5 ± 45.9 10 10
SPEC 1.0 1.0 1125.9 ± 29.3a 50a 50a
Values are mean ± S.E.M. (n = 7 per group). aP < 0.05 (ANOVA followed by 
Student-Neuman-Keuls t-test) compared to control; bP < 0.001 (Fisher`s test) 
compared to control
Figure 3: Time (s) on the Rota-rod observed in mice after oral 
route treatment with Vehicle (control), iso-6-spectaline (0.1, 0.5 and 
1.0 mg/  kg, p.o., SPEC) or DZP (2.0 mg/kg, i.p.). The motor response 
was recorded for the following 180 s after drug treatment. Values are 
mean ± S.E.M. for seven mice per group. *P < 0.001 as compared 
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probably through a competitive agonist action in the BZD 
site of the GABA receptors. The significant effect on the 
motor coordination, in high doses, might support this 
theory, as GABAergic drugs usually are sedative.[30]
According to previous studies, picrotoxin, a GABAA-receptor 
antagonist, produces seizures by blocking the chloride-ion 
channels linked to GABAA-receptors, preventing the entry 
of chloride ions into the brain and, consequently, inhibitory 
transmission in the brain.[31] Therefore, the findings of the 
present study suggest that SPEC (1.0 mg/kg, p.o.) might have 
inhibited and/or attenuated the PIC-induced convulsions by 
interfering with GABAergic neurotransmission.[32]
Summarizing our data, the results suggest depressant CNS and 
anticonvulsant effects of iso-6-spectaline from Senna spectabilis. 
The precise mechanisms of the possible behavioral effects 
of iso-6-spectaline are not clear, however, the GABAergic 
neurotransmitter system might be involved. So, more studies 
will be required for elucidation of this effect in the CNS.
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